boehringer ingelheim glp-1 ADA: Tolerability questions linger for Boehringer's obesity drug Boehringer dual-acting obesity shot hits
Description
Disclosure: Ryan Costello declares no relevant financial relationships with ineligible companies.: StatPearls Publishing
Slowing the rate by eating more, not by reducing medication, is usually the better approach
doi: 10.1080/00207454.2021.1924707 [DOI] [PubMed] [Google Scholar] 86
An alternative approach aiming to maximize the efficacy of GLP-1 involves the delivery of nuclear receptor agonists to specific tissues characterized by the expression of GLP-1R
In July 2023, the FDA announced it was reviewing reports of stomach paralysis associated with GLP-1 drugs, including Ozempic and Wegovy
